Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 18/20 | 0.79 |
| ▸ | DGKZ | Q13574 | 18/20 | 0.79 |
| ▸ | DGKI | O75912 | 3/20 | 0.79 |
| ▸ | DGKG | P49619 | 2/20 | 0.79 |
| ▸ | DGKB | Q9Y6T7 | 2/20 | 0.79 |
| ▸ | DGKK | Q5KSL6 | 1/20 | 0.79 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23293193 | 1.00 | DGKA (0.79) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL30616405 | 0.94 | DGKA (0.76) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293461 | 0.94 | DGKA (0.76) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293137 | 0.92 | DGKZ (0.69) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL30616374 | 0.92 | DGKZ (0.69) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293169 | 0.88 | DGKA (0.78) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL30616381 | 0.88 | DGKA (0.78) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL21830991 | 0.88 | DGKA (1.00) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL29654799 | 0.88 | DGKA (1.00) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293410 | 0.85 | DGKZ (0.67) | DGKADGKZDGKIDGKGDGKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | claimed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |